Metabolic complications of antiretroviral therapy in children

Pediatr Infect Dis J. 2003 Jan;22(1):77-84. doi: 10.1097/00006454-200301000-00018.

Abstract

Survival in HIV-infected children has greatly improved with the introduction of highly active antiretroviral therapy. Children are more vulnerable than adults to metabolic side effects of therapy because of its potential impact on growth and the children's likely greater cumulative exposure. This review summarizes the epidemiology and management of lipodystrophy, dyslipidemia, insulin resistance, hyperlactatemia, osteopenia and growth failure in HIV-infected children.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Anti-HIV Agents / adverse effects*
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Bone Diseases, Metabolic / drug therapy
  • Bone Diseases, Metabolic / etiology
  • Child
  • Contraindications
  • Growth Disorders / drug therapy
  • Growth Disorders / etiology
  • HIV / drug effects
  • HIV / pathogenicity
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Hyperlipidemias / drug therapy
  • Hyperlipidemias / etiology
  • Insulin Resistance / physiology
  • Lipodystrophy / drug therapy
  • Lipodystrophy / etiology
  • Reverse Transcriptase Inhibitors / therapeutic use

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors